Medicure Inc. (CVE:MPH – Get Free Report)’s share price reached a new 52-week high during trading on Tuesday. The company traded as high as C$4.95 and last traded at C$4.36, with a volume of 5,760 shares. The stock had previously closed at C$2.98.
Medicure Stock Up 46.3%
The company has a current ratio of 0.97, a quick ratio of 1.28 and a debt-to-equity ratio of 6.02. The firm has a market cap of C$45.50 million, a price-to-earnings ratio of -6.06 and a beta of 0.98. The firm has a 50-day moving average of C$2.21 and a two-hundred day moving average of C$1.53.
About Medicure
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
Recommended Stories
- Five stocks we like better than Medicure
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
- IonQ Fell 9% on a $1.3 Billion Deal—Is Wall Street Missing Something?
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
